期刊文献+

氯沙坦与美托洛尔对高血压心肌肥厚影响的实验研究 被引量:4

下载PDF
导出
摘要 目的研究氯沙坦与美托洛尔联合对高血压心肌肥厚的干预作用。方法采用结扎大鼠腹主动脉法造模,将Wistar雄性大鼠50只随机分为似手术对照组、模型组、氯沙坦组、美托洛尔组、氯沙坦+美托洛尔组,治疗5周后测定血流动力学、左心室肥厚程度、血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)及胶原蛋白含量的变化,同时检测血清中细胞因子(白细胞介素-6、白细胞介素-10、肿瘤坏死因子-α)水平变化。结果治疗5周后,与模型组比较,氯沙坦组、美托洛尔组、氯沙坦+美托洛尔组的收缩压、舒张压、平均动脉压较模型组均降低;心脏质量/体质量与左室质鞋/体质量亦有所降低;AngⅡ及胶原蛋白含量明显降低;白细胞介素-6、肿瘤坏死因子-α水平降低;氯沙坦+美托洛尔组效果最明显。结论氯沙坦与美托洛尔能干预心肌肥厚,改善血流动力学,两者合用具有协同作用。
作者 李祯 李润梅
出处 《河北医科大学学报》 CAS 2012年第2期228-230,共3页 Journal of Hebei Medical University
  • 相关文献

参考文献7

二级参考文献57

  • 1冯俊,郑智,熊玮.丹参酮ⅡA预防自发性高血压大鼠左室肥厚的机制[J].中国急救医学,2005,25(11):820-822. 被引量:5
  • 2Lorell BH,Carabello BA.Left ventricular hypertrophy:pathogenesis,detection,and prognosis.Circulation,2000,102:470-479.
  • 3Wollert KC,Drexler H.Regulation of cardiac remodeling by nitric oxide:focus on cardiac myocite hypertrophy and apaptosis.Heart Fail Rev,2002,7:317-325.
  • 4Kempf T,Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy.Bioessays,2004,6:608-615.
  • 5Russell B,Motlagh D,Ashley WW.Form follows function:how muscle shape is regulated by work.J Appl Physiol,2000,88:1127-1132.
  • 6Ozaki M,Kawashirna S,Yamashita T,Hirase T,Ohashi Y,Inone N,et al.Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion.Circ J,2002,66:851-856.
  • 7Von Harsdorf R,Kang RE,Fullerton M,Woodcock EA.Myocardial stretch stimulates phoephatidyl-inositol turnover.Circ Res,1989,65:494-501.
  • 8Sussman A,Mcculloch A,Borg TK.Dance band on the titanic:biomechanical signaling in cardiac hypertrophy.Cire Res,2002,91:888-898.
  • 9Burridge K,Chrzanowska-Wodnicka M.Focal adhesions,contractility,and signaling.Anna Rev Cell Dev Biol,1996,12:463-519.
  • 10Campos LA,lliescu 8,Fontes M,Sehlegel WP,Bader M,Baltstu OC.Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.Am J Physiol Heart Cite Physiol,2006,291 (5):H2371-2376.

共引文献52

同被引文献63

  • 1Oka T,Akazawa H,Naito AT,et al.Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure[J].Circ Res, 2014,114(3) : 565 - 571.
  • 2Berenji K, Drazner MH, Rothermel BA, et al. Does load- induced ventrieular hypertrophy progress to systolic heart failure? [J].Am J Physiol Heart Circ Physiol, 2005,289 (1) : 8-16.
  • 3Lu M, Wang H, Wang J, et al. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca^2+/CaN signaling pathway[J].Planta Med, 2014,80 (1) : 63- 69.
  • 4Pellicena P, Schulman H.CaMK Ⅱ inhibitions: from research tools to therapeutic agents[J].Front Pharmacol, 2014,5:21.
  • 5Hardt SE, Sadoshima J. Negative regulators of cardiac hypertrophy[J].Cardiovasc Res, 2004,63 (3) : 500- 509.
  • 6Sundqvist A,Ten Dijke P,van Dam H.Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity[J].Breast Cancer Res, 2012,14(1) :204.
  • 7Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor(TGF)-β signaling in cardiac remodeling[J].J Mol Cell Cardiol, 2011,5 1 (4) : 600 - 606.
  • 8Goldstein JA, Kelly SM, LoPresti PP, et al. SMAD signaling drives heart and muscle dysfunction in a drosophila model of muscular dystrophy[J]. Hum Mol Genet, 2011,20 (5) : 894 - 904.
  • 9Biernaeka A, Dohaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis[J].Growth Factors, 2011,29 (5) : 196 - 202.
  • 10Villar AV, Llano M, Cobo M, et al. Gender differences of echocardiographie and gene expression patterns in human pressure overload left ventricular hypertrophy[J].J Mol Cell Cardiol, 2009,46 (4) : 526- 535.

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部